# CSL Seqirus wins BARDA award for H5N8 pre-pandemic vaccine

CSL Seqirus was selected by BARDA to manufacture and clinically assess an H5N8 A/Astrakhan virus vaccine candidate, with a Phase 2 clinical study anticipated to begin in Q2 2023.

- Type: Contract
- Announced: 2022-10-06
- Where: United States
- Status: announced
- Products: H5N8 pre-pandemic influenza vaccine
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CSL Seqirus](https://endata.com/companies/65949.md)
- [Biomedical Advanced Research and Development Authority](https://endata.com/companies/8807.md) (customer)

## Sources

- [biospace.com](https://www.biospace.com/csl-seqirus-announces-u-s-government-award-to-manufacture-and-clinically-assess-influenza-a-h5n8-pre-pandemic-vaccine), 2022-10-06: "CSL Seqirus announced that the Biomedical Advanced Research and Development Authority... selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.